I'm LongbridgeAI, I can summarize articles.Merck (MRK) added 1.33% this week to close at $150.33, outperforming the S&P 500 by roughly 1.24 percentage points. The stock moved in a rise-then-fade pattern across 4.66% of weekly amplitude. Monday opened at $147.00 and dipped to $145.95 before recovering; Tuesday and Wednesday pushed higher on heavier volume, with Wednesday peaking at $152.69. Thursday gapped up to $152.80 but could not hold, finishing at $152.34, before Friday eased back to the $150.33 close.
The Week
Merck (MRK) added 1.33% this week to close at $150.33, outperforming the S&P 500 by roughly 1.24 percentage points. The stock moved in a rise-then-fade pattern across 4.66% of weekly amplitude. Monday opened at $147.00 and dipped to $145.95 before recovering; Tuesday and Wednesday pushed higher on heavier volume, with Wednesday peaking at $152.69. Thursday gapped up to $152.80 but could not hold, finishing at $152.34, before Friday eased back to the $150.33 close. Average daily turnover of around 8.17m shares sat 15.97% below the prior median, pointing to thin participation.
Key Events
The week’s news flow centred on Keytruda (pembrolizumab) competition and Merck’s oral PCSK9 franchise. On Wednesday, data from the HARMONi-2 study run by Akeso in China showed a statistically significant overall survival benefit for Ivonescimab monotherapy versus Keytruda monotherapy in PD-L1-positive advanced NSCLC; by Thursday, some market commentary pushed back that the signal was not fully accepted. Separately, India’s Cipla and China’s Qilu partnered for a US launch of a Keytruda biosimilar, adding another layer on the generics side. DelveInsight noted the oral PCSK9 market has entered a high-growth phase following Merck’s LIPFENDRA approval and the emergence of programmes such as AstraZeneca’s AZD0780. Merck also said it would participate in the Wells Fargo 21st Annual Healthcare Conference without disclosing specific agenda items.
Analyst Ratings
Coverage on Merck totals 28 firms: 15 rate it buy, 5 overweight, 8 hold, with no underweight or sell ratings. The consensus recommendation is buy, with a consensus target of $148.73, about 1.06% below the current price of $150.33. The target range is wide, from $105.00 to $186.00, underscoring a split view on Keytruda’s longer-term growth and biosimilar pressure. Among 205 companies in the pharmaceutical industry, Merck ranks 4th by analyst rating.
The Week Ahead
The macro calendar turns dense next week, led by Thursday 10 September: US final demand PPI, core final demand PPI, initial jobless claims, existing home sales, plus a 10-year Treasury auction. For Merck itself, the next earnings release is fiscal Q3 2026, expected on 29 October before the open, with consensus estimates near $1.90 EPS and about $17.3bn revenue. Until then, follow-through debate on Keytruda competition and oral PCSK9 progress remains the main swing factor.
In Short
Merck edged higher this week, but the tension between ratings and price remains. Consensus is buy and the industry ranking is strong, yet the consensus target sits slightly below spot and the target range spans $81, reflecting a wide gap in views on Keytruda’s durability and biosimilar impact. Volume was light relative to the prior median, so neither flows nor sentiment offered a clean directional signal. The next test is whether the October earnings release narrows that spread, alongside further updates on Keytruda competition and the oral PCSK9 pipeline.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.